An interventional study of Chlorine dioxide mouthwash and Chlorhexidine mouthwash in Halitosis, sponsored by Semmelweis University. Enrolling by invitation at 1 site in Hungary. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-05.
Sponsored by Semmelweis University · Not applicable, Interventional, and Supportive care
The ODOR trial will be a single-centric, double-blinded, parallel-group, double-armed pilot randomized controlled trial with a non-inferiority design. The efficacy of hyperpure chlorine dioxide will be compared to chlorhexidine mouthwash. The short-term effect of the mouthwashes will be investigated in a 3-hour-long period. The primary endpoint will be the changes in the organoleptic testing scores.
Eligible patients will be randomly allocated to two groups in a 1:1 ratio. Necessary data will be collected with prespecified electronic case report forms (REDCap). The statistician will calculate the sample size at the end of the pilot investigation of the first 30-30 patients. If feasible, investigators will continue the study by enrolling more patients.
93 studies on the registry are indexed under Halitosis; 17 are open to participants now.
This study's planned enrollment of 60 is above the median of 45 across 79 interventional studies indexed under Halitosis.
Browse Halitosis studies →Semmelweis University is the lead sponsor of 140 studies on the registry; 56 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will rinse once with hyper-pure ClO2 (0.003%) mouthwash.
Procedure: Chlorine dioxide mouthwash
Participants will rinse once with chlorhexidine-containing mouthwash (0.2%).
Procedure: Chlorhexidine mouthwash
This one rinsing will last 2x15 seconds(2x12,5ml).
Also known as: Solumium Coral®
This one rinsing will last 2x15 seconds(2x12,5ml).
Also known as: Curasept ADS 220, 0.2%
Changes of the organoleptic testing scores
(gold standard 6-point (0-5) intensity scale. The examiner rates it 0 when the patient has no halitosis, and 5 when it is very severe)
Time frame: immediately after the rinse and 3 hours later
Changes of the volatile sulfur compounds
with gas chromatography
Time frame: immediately after the rinse and 3 hours later
Self-perceived halitosis
with a visual analog scale ratings (0-100, 0 = No Pain, 100 = Worst Possible Pain)
Time frame: immediately after the rinse and 3 hours later
Side effects
(e.g., tooth discoloration, signs of allergic reactions, subjective experiences: unpleasant taste, false taste or burning sensation, pain, changes in salivary flow)
Time frame: immediately after the rinse and 3 hours later
Plan to share: No
Started Apr 2024 (actual). Primary completion is estimated for Dec 2025, 20 months after the start.
Of 35 non-industry interventional studies with no phase under Halitosis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 18. This study's planned 20 months is above that.
Counting every sponsor, half of 43 studies reached it within 10 months; a quarter within 3 and three quarters within 18.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.